Publication date: Mar 24, 2025
This study investigates the prevalence and clinical features of advanced Parkinson’s disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG). We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility. This study included 370 patients with Parkinson’s disease, of whom 44. 6% (95%CI: 39. 5%-49. 8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1. 08, p = 0. 047). Overall, 38. 9% of patients qualified for at least one DAT, including 18. 9% for DBS, 35. 4% for CSAI, and 13. 8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0. 93, p
| Concepts | Keywords |
|---|---|
| Carbidopa | deep brain stimulation |
| Increased | device-aided therapies |
| Morocco | levodopa-carbidopa Intestinal gel |
| Parkinson | Morocco |
| Therapy |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Parkinson’s disease |
| drug | DRUGBANK | Apomorphine |
| drug | DRUGBANK | Levodopa |
| drug | DRUGBANK | Carbidopa |
| disease | MESH | disease progression |